Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2016

Open Access 01-12-2016 | Study protocol

Design and protocol for the Dialysis Optimal Health Program (DOHP) randomised controlled trial

Authors: Simon R. Knowles, Chantal F. Ski, Robyn Langham, Emmet O’Flaherty, David R. Thompson, Susan L. Rossell, Gaye Moore, Ya-seng (Arthur) Hsueh, David J. Castle

Published in: Trials | Issue 1/2016

Login to get access

Abstract

Background

Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are serious and growing health problems with enormous impact on psychological and social functioning. Despite high rates of comorbid depression and anxiety in these patient populations, and the adverse impact these have upon treatment adherence, quality of life, social connectedness and healthcare costs there has been little attention focused on the prevention or management of these problems. Thus, our aim was to evaluate the Dialysis Optimal Health Program (DOHP) that adopts a person-centred approach and engages collaborative therapy to educate and support those diagnosed with ESKD who are commencing dialysis.

Methods

The study design is a randomised controlled trial. Ninety-six adult patients initiating haemodialysis or peritoneal dialysis will be randomly allocated to either the intervention (DOHP) or usual care group. Participants receiving the intervention will receive nine (8 + 1 booster session) sequential sessions based on a structured information/workbook, psychosocial and educational supports and skills building. The primary outcome measures are depression and anxiety (assessed by the Hospital Anxiety and Depression Scale; HADS). Secondary outcomes include health-related quality of life (assessed by the Kidney Disease Quality of Life instrument; KDQOL), self-efficacy (assessed by General Self-Efficacy Scale) and clinical indices (e.g. albumin and haemoglobin levels). Cost-effectiveness analysis and process evaluation will also be performed to assess the economic value and efficacy of the DOHP. Primary and secondary measures will be collected at baseline and at 3-, 6-, and 12-month follow-up time points.

Discussion

We believe that this innovative trial will enhance knowledge of interventions aimed at supporting patients in the process of starting dialysis, and will broaden the focus from physical symptoms to include psychosocial factors such as depression, anxiety, self-efficacy, wellbeing and community support. The outcomes associated with this study are significant in terms of enhancing an at-risk population’s psychosocial health and reducing treatment-related costs and associated pressures on the healthcare system.

Trial registration

ANZCTR no. 12615000810516. Registered on 5 August 2015.
Appendix
Available only for authorised users
Literature
1.
Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011; 8:1258–70.CrossRef
2.
Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease— Australian facts: prevalence and incidence, cardiovascular, diabetes and chronic kidney disease series no. 2. Cat. no. CDK 2. Canberra: AIHW; 2014.
3.
ANZDATA Registry. 37th Report, Chapter 1: Incidence of End Stage Kidney Disease. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2015. Available at: http://​www.​anzdata.​org.​au
4.
Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol. 1993; 4(1):12–27.PubMed
5.
Christensen AJ, Ehlers SL. Psychological factors in end-stage renal disease: an emerging context for behavioral medicine research. J Consult Clin Psychol. 2002; 70(3):712–24.CrossRefPubMed
6.
Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Boyle DH, Umana WO, Kovac JA, Alleyne S, Cruz I, Veis JH. Psychologic functioning, quality of life, and behavioral compliance in patients beginning hemodialysis. J Am Soc Nephrol. 1996; 7(10):2152–9.PubMed
7.
Low J, Smith G, Burns A, Jones L. The impact of end-stage kidney disease (ESKD) on close persons: a literature review. NDT Plus. 2008; 2:67–79.
8.
Stasiak CES, Bazan KS, Kuss RS, Schuinski AFM, Baroni G. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014; 36(3):325–31.CrossRefPubMed
9.
Levenson JL, Glocheski S. Psychological factors affecting end-stage renal disease. A review Psychosomatics. 1991; 32(4):382–9.CrossRefPubMed
10.
Knowles S, Swan L, Salzberg M, Castle D, Langham R. Exploring the relationships between health status, illness perceptions, coping strategies and psychological morbidity in a chronic kidney disease cohort. Am J Med Sci. 2014; 348(4):271–6.CrossRefPubMed
11.
Cukor D, Cohen SD, Peterson RA, Kimmel PL. Psychosocial aspects of chronic disease: ESRD as a paradigmatic illness. J Am Soc Nephrol. 2007; 18(12):3042–55.CrossRefPubMed
12.
Bossola M, Ciciarelli C, Di Stasio E, Conte GL, Vulpio C, Luciani G, Tazza L. Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. Gen Hosp Psychiatry. 2010; 32(2):125–31.CrossRefPubMed
13.
Lopes AA, Albert JM, Young EW, Satayathum S, Pisoni RL, Andreucci VE, Mapes DL, Mason NA, Fukuhara S, Wikstrom B, et al. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int. 2004; 66(5):2047–53.CrossRefPubMed
14.
Lacson E Jr, Li NC, Guerra-Dean S, Lazarus M, Hakim R, Finkelstein FO. Depressive symptoms associate with high mortality risk and dialysis withdrawal in incident hemodialysis patients. Nephrol Dial Transplant. 2012; 27(7):2921–8.CrossRefPubMed
15.
Chilcot J, Davenport A, Wellsted D, Firth J, Farrington K. An association between depressive symptoms and survival in incident dialysis patients. Nephrol Dial Transplant. 2010; 26(5):1628–34.CrossRefPubMed
16.
Bonner A, Havas K, Douglas C, Thepha T, Bennett P, Clark R. Self-management programmes in stages 1–4 chronic kidney disease: a literature review. J Ren Care. 2014; 40(3):194–204.CrossRefPubMed
17.
Sareen J, Jacobi F, Fox B, Belik S, Clara I, Stein M. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006; 166:2109–16.CrossRefPubMed
18.
McKercher C, Sanderson K, Jose MD. Psychosocial factors in people with chronic kidney disease prior to renal replacement therapy. Nephrology. 2013; 18:585–91.CrossRefPubMed
19.
Rabindranath KS, Daly C, Butler JA, Roderick PJ, Wallace S, Macleod AM. Psychosocial interventions for depression in dialysis patients. Cochrane Database Syst Rev. 2005; 3:CD004542.PubMed
20.
Kimmel PL, Peterson RA. Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived? Clin J Am Soc Nephrol. 2006; 1(3):349–52.CrossRefPubMed
21.
Castle D, Gilbert M. Collaborative therapy: framework for mental health. Br J Psychiatry. 2006; 189:467.CrossRefPubMed
22.
Castle D, White C, Chamberlain J, Berk M, Berk L, Lauder S, Murray G, Schweitzer I, Piterman L, Gilbert M. Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. Br J Psychiatry. 2010; 196:383–8.CrossRefPubMed
23.
Gilbert M, Chamberlain J, White C, Mayers P, Pawsey B, Liew D, Musgrave M, Crawford K, Castle D. Controlled clinical trial of a self-management program for people with mental illness in an adult mental health service–the optimal health program (OHP). Aust Health Rev. 2012; 36:1–7.CrossRefPubMed
24.
Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E, Bonara LI, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC. Reliability and validity of the M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.): according to the SCID-P. Eur Psychiatry. 1997; 12:232–41.CrossRef
25.
Richardson J, Peacock S, Hawthorne G, Iezzi A, Elsworth G, Atherton DN. Construction of the descriptive system for the assessment of quality of life: AQoL-6D utility instrument. Health Qual Life Outcomes. 2012; 10(38):1–9.
26.
Konerding U, Elkhuizen S, Faubel R, Forte P, Malmström T, Pavi E, Janssen M. The validity of the EQ-5D-3 L items: an investigation with type 2 diabetes patients from six European countries. Health Qual Life Outcomes. 2014; 12:181.CrossRefPubMedPubMedCentral
27.
Diggle P, Heagerty P, Liang K, Zeger S. Analysis of longitudinal data. 2nd ed. Oxford: Oxford University Press; 2002.
28.
Schulz FK, Altman GD, Mother D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010; 152(11):1–8.CrossRef
29.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361–70.CrossRefPubMed
30.
Hays RD, et al. Kidney Disease Quality of Life Short Form (KDQOL-SF™), version 1.3: a manual for use and scoring. Santa Monica: RAND; 1997: p. 7994.
31.
Bosscher RJ, Smit JH. Confirmatory factor analysis of the General Self-Efficacy Scale. Behav Res Ther. 1998; 36(3):339–43.CrossRefPubMed
32.
Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006; 60:631–7.CrossRefPubMed
33.
Carver C, Scheier M, Weintraub J. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989; 56:267–83.CrossRefPubMed
34.
Carver C. You want to measure coping but your protocol’s too long: consider the Brief COPE. Int J Behav Med. 1997; 4:92–100.CrossRefPubMed
35.
Gosling S, Rentfrow P, Swann W Jr. A very brief measure of the big five personality domains.J Res Pers. 2003; 37:504–28.CrossRef
36.
Mundt J, Marks I, Shear K, Greist J. The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002; 180:461–4.CrossRefPubMed
37.
Devilly G, Borkovec T. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000; 31:73–86.CrossRefPubMed
38.
Newton J, Sturmey P. Development of a short form of the Treatment Evaluation Inventory for acceptability of psychological interventions. Psychol Rep. 2004; 94:47–81.CrossRef
39.
Hsueh A. Health Care Utilisation Questionnaire (HCUQ) based on Thorn JC, Coast J, Cohen D, Hollingworth W, Knapp M, Noble SM, Ridyard C, Wordsworth S, Hughes D. Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation. Appl Health Econ Health Policy. 2013;11:155–61.
40.
Nich C, Carroll K. Now you see it, now you don’t: a comparison of traditional versus random-effects regression models in the analysis of longitudinal follow-up data from a clinical trial. J Consult Clin Psychol. 1997; 65(2):252–61.CrossRefPubMed
41.
Schafer J, Graham J. Missing data: our view of the state of the art. Psychol Methods. 2002; 7(2):147–77.CrossRefPubMed
Metadata
Title
Design and protocol for the Dialysis Optimal Health Program (DOHP) randomised controlled trial
Authors
Simon R. Knowles
Chantal F. Ski
Robyn Langham
Emmet O’Flaherty
David R. Thompson
Susan L. Rossell
Gaye Moore
Ya-seng (Arthur) Hsueh
David J. Castle
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Trials / Issue 1/2016
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-016-1558-z

Other articles of this Issue 1/2016

Trials 1/2016 Go to the issue

Study protocol

The beneficial effects of cognitive training with simple calculation and reading aloud in an elderly postsurgical population: study protocol for a randomized controlled trial

Study protocol

The BBaRTS Healthy Teeth Behaviour Change Programme for preventing dental caries in primary school children: study protocol for a cluster randomised controlled trial

Study protocol

An illness-focused interactive booklet to optimise management and medication for childhood fever and infections in out-of-hours primary care: study protocol for a cluster randomised trial

Study protocol

Intrathoracic versus Cervical ANastomosis after minimally invasive esophagectomy for esophageal cancer: study protocol of the ICAN randomized controlled trial

Study protocol

Evaluating optimal patient-turning procedures for reducing hospital-acquired pressure ulcers (LS-HAPU): study protocol for a randomized controlled trial

Research

A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers